Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Chemotherapy's hidden toll on blood vessels revealed

NCT ID NCT03062878

Knowledge-focused Sponsor: Carl Ade, M.S., Ph.D. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at how anthracycline-based chemotherapy affects blood vessel health and blood pressure control in 60 people with breast cancer or lymphoma. Researchers measured artery stiffness, blood flow, and skin blood vessel responses. The goal is to understand why cancer survivors face higher heart disease risk and find ways to reduce it.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors understand how chemotherapy harms blood vessels, leading to better ways to protect heart health in cancer survivors.
What could go wrong
This is an observational study, not a treatment trial. It only measures changes and does not test any new therapy, so it cannot directly improve patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

60 people

The number who actually took part.

Started

Feb 2017

Finished

Aug 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Breast cancer and lymphoma patients (n =20) will enter the study following completion of at least 1 cycle of chemotherapy. Breast cancer and lymphoma survivors (n=20) will enter study if they are 1 - 5 years removed from last date of chemotherapy. Healthy control subjects (n=20) will be included in the study.

Ages

21 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Give voluntary consent to participate in the study * (Group 1) Diagnosed Stage I-III breast cancer or lymphoma cancer with a \> 2 year life expectancy * (Group 1) Current chemotherapy treatment includes anthracyclines * (Group 2) History of Stage I-III breast cancer or lymphoma cancer with a \> 2 year life expectancy * (Group 2) 1 - 5 years removed from last date of anthracycline-based chemotherapy Exclusion Criteria: * History of clinical cardiovascular disease (Atherosclerotic cardiovascular disease (ASCVD) defined by history of acute coronary syndromes, myocardial infarction (MI), stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemia attack (TIA), or peripheral arterial disease presumed to be of atherosclerotic origin) * Not met the above criteria * Unable to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm chemotherapy-induced toxicity lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Chemotherapy effect Lymphoma

Contacts and locations

Locations

  • Lafene Health Center

    Manhattan, Kansas, 66502, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.